[
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-22 09:30:00",
    "publisher": "Seeking Alpha",
    "title": "AbbVie: Spotlight On Rinvoq Ahead Of Q3 Earnings",
    "image": "https://images.financialmodelingprep.com/news/abbvie-spotlight-on-rinvoq-ahead-of-q3-earnings-20211022.jpg",
    "site": "seekingalpha.com",
    "text": "AbbVie has grown to become a $190bn market cap pharma since it was spun out of Abbott Laboratories in 2012. Its share price is up 210% overall. The company's prime asset, Humira, will go off patent in the US in 2023. This will drop its ~$20bn annual revenues by ~20% per annum over a five-year period.",
    "url": "https://seekingalpha.com/article/4461241-abbvie-spotlight-on-rinvoq-a-key-element-of-mgmts-plan-to-replace-humira-sales-ahead-of-q3-results",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-22T09:30:00-04:00",
    "date_et": "2021-10-22"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-22 16:08:28",
    "publisher": "Zacks Investment Research",
    "title": "AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?",
    "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-earnings-expected-to-grow-should-you-buy-20211022.jpg",
    "site": "zacks.com",
    "text": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://www.zacks.com/stock/news/1815363/abbvie-abbv-earnings-expected-to-grow-should-you-buy",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-22T16:08:28-04:00",
    "date_et": "2021-10-22"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-25 06:39:00",
    "publisher": "The Motley Fool",
    "title": "What Could These Clinical Results Mean for AbbVie's Shareholders?",
    "image": "https://images.financialmodelingprep.com/news/what-could-these-clinical-results-mean-for-abbvies-shareholders-20211025.jpg",
    "site": "fool.com",
    "text": "The results from phase 3 clinical trials suggest that Rinvoq could be an effective treatment for patients.",
    "url": "https://www.fool.com/investing/2021/10/25/what-could-these-clinical-results-mean-for-abbvies/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-25T06:39:00-04:00",
    "date_et": "2021-10-25"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-25 10:40:23",
    "publisher": "24/7 Wall Street",
    "title": "5 Buy-Rated Blue Chips Are Raising Their Dividends This Week",
    "image": "https://images.financialmodelingprep.com/news/5-buyrated-blue-chips-are-raising-their-dividends-this-20211025.jpg",
    "site": "feedproxy.google.com",
    "text": "After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream. What this equates to is total return, which is one of the most powerful investment strategies going.",
    "url": "https://feedproxy.google.com/~r/typepad/RyNm/~3/zdUiMjcxKL4/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-25T10:40:23-04:00",
    "date_et": "2021-10-25"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-25 11:19:16",
    "publisher": "Benzinga",
    "title": "Will Chart Analysts Notice Bad Omen on AbbVie's Chart",
    "image": "https://images.financialmodelingprep.com/news/will-chart-analysts-notice-bad-omen-on-abbvies-chart-20211025.jpg",
    "site": "benzinga.com",
    "text": "If history is any guide, there may be trouble ahead for shares of AbbVie(NYSE:ABBV). A so-called \"death cross\" has formed on its chart and, not surprisingly, this could be bearish for the stock.",
    "url": "https://www.benzinga.com/markets/21/10/23534196/will-chart-analysts-notice-bad-omen-on-abbvies-chart",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-25T11:19:16-04:00",
    "date_et": "2021-10-25"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-25 19:15:37",
    "publisher": "Zacks Investment Research",
    "title": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know",
    "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-stock-sinks-as-market-gains-what-you-20211025.jpg",
    "site": "zacks.com",
    "text": "AbbVie (ABBV) closed at $108.50 in the latest trading session, marking a -0.59% move from the prior day.",
    "url": "https://www.zacks.com/stock/news/1816224/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-25T19:15:37-04:00",
    "date_et": "2021-10-25"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-25 20:00:13",
    "publisher": "Zacks Investment Research",
    "title": "Buy This Great High-Yield Dividend Stock?",
    "image": "https://images.financialmodelingprep.com/news/buy-this-great-highyield-dividend-stock-20211025.jpg",
    "site": "zacks.com",
    "text": "Investors in search of stable income should consider strong dividend-paying stocks, with solid yields. Pharmaceutical standout AbbVie appears to be worth buying as a long-term play, with it set to release its Q3 results on Friday, October 29.",
    "url": "https://www.zacks.com/stock/news/1816288/buy-this-great-high-yield-dividend-stock",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-25T20:00:13-04:00",
    "date_et": "2021-10-25"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-26 06:45:00",
    "publisher": "The Motley Fool",
    "title": "Was Atea Pharmaceutical's Flop Predictable?",
    "image": "https://images.financialmodelingprep.com/news/was-atea-pharmaceuticals-flop-predictable-20211026.jpg",
    "site": "fool.com",
    "text": "Were warning signs there for investors all along?",
    "url": "https://www.fool.com/investing/2021/10/26/was-atea-pharmaceuticals-flop-predictable/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-26T06:45:00-04:00",
    "date_et": "2021-10-26"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-26 10:20:38",
    "publisher": "InvestorPlace",
    "title": "The 7 Best Stocks to Buy to Profit From the Rich",
    "image": "https://images.financialmodelingprep.com/news/the-7-best-stocks-to-buy-to-profit-from-20211026.jpg",
    "site": "investorplace.com",
    "text": "With the pandemic unintuitively minting new millionaires, you can either get jealous or ride the wave with these stocks to buy. The post The 7 Best Stocks to Buy to Profit From the Rich appeared first on InvestorPlace.",
    "url": "https://investorplace.com/2021/10/skip-jealousy-7-best-stocks-to-buy-profit-from-rich/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-26T10:20:38-04:00",
    "date_et": "2021-10-26"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-26 12:35:19",
    "publisher": "Zacks Investment Research",
    "title": "AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?",
    "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-to-report-q3-earnings-whats-in-the-20211026.jpg",
    "site": "zacks.com",
    "text": "AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.",
    "url": "https://www.zacks.com/stock/news/1816815/abbvie-abbv-to-report-q3-earnings-what-s-in-the-cards",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-26T12:35:19-04:00",
    "date_et": "2021-10-26"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-26 13:39:31",
    "publisher": "InvestorPlace",
    "title": "7 High-Yield Stock Gems for Income-Obsessed Investors",
    "image": "https://images.financialmodelingprep.com/news/7-highyield-stock-gems-for-incomeobsessed-investors-20211026.jpg",
    "site": "investorplace.com",
    "text": "Investors seeking big payouts should consider these seven high-yield stocks from various sectors. They range from pharmaceuticals to REITs.",
    "url": "https://investorplace.com/2021/10/seven-high-yield-stock-gems-for-income-obsessed-investors/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-26T13:39:31-04:00",
    "date_et": "2021-10-26"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-27 07:52:00",
    "publisher": "The Motley Fool",
    "title": "AbbVie Takes Another Step Toward Its Post-Humira Future",
    "image": "https://images.financialmodelingprep.com/news/abbvie-takes-another-step-toward-its-posthumira-future-20211027.jpg",
    "site": "fool.com",
    "text": "Skyrizi is an important drug for AbbVie's future that could soon be approved for another indication in the E.U.",
    "url": "https://www.fool.com/investing/2021/10/27/abbvie-takes-big-step-toward-post-humira-future/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-27T07:52:00-04:00",
    "date_et": "2021-10-27"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-27 12:58:33",
    "publisher": "Zacks Investment Research",
    "title": "Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings",
    "image": "https://images.financialmodelingprep.com/news/recovery-in-drugs-sales-to-aid-abbvies-abbv-q3-20211027.jpg",
    "site": "zacks.com",
    "text": "AbbVie (ABBV) is expected to have witnessed a recovery in demand trends of new drugs amid the receding impact of the pandemic. However, sales of physician-administered drugs are likely to have been hurt by the residual impact.",
    "url": "https://www.zacks.com/stock/news/1817737/recovery-in-drugs-sales-to-aid-abbvie-s-abbv-q3-earnings",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-27T12:58:33-04:00",
    "date_et": "2021-10-27"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-27 12:58:36",
    "publisher": "Zacks Investment Research",
    "title": "Healthcare ETFs in Focus as Q3 Earnings Unfold",
    "image": "https://images.financialmodelingprep.com/news/healthcare-etfs-in-focus-as-q3-earnings-unfold-20211027.jpg",
    "site": "zacks.com",
    "text": "The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.",
    "url": "https://www.zacks.com/stock/news/1817615/healthcare-etfs-in-focus-as-q3-earnings-unfold",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-27T12:58:36-04:00",
    "date_et": "2021-10-27"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-28 07:15:00",
    "publisher": "Seeking Alpha",
    "title": "AbbVie: Fears Are Overblown, It's Time To Buy This High-Yielder",
    "image": "https://images.financialmodelingprep.com/news/abbvie-fears-are-overblown-its-time-to-buy-this-20211028.jpg",
    "site": "seekingalpha.com",
    "text": "AbbVie: Fears Are Overblown, It's Time To Buy This High-Yielder",
    "url": "https://seekingalpha.com/article/4462690-abbvie-stock-fears-overblown-time-to-buy-this-high-yielder",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-28T07:15:00-04:00",
    "date_et": "2021-10-28"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-28 08:15:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease",
    "image": "https://images.financialmodelingprep.com/news/abbvie-announces-abbv951-foslevodopafoscarbidopa-showed-improvement-in-controlling-motor-20211028.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Oct. 28, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with advanced Parkinson's disease (PD) in a Phase 3, randomized, double-blind, double-dummy, active-controlled study.",
    "url": "https://www.prnewswire.com/news-releases/abbvie-announces-abbv-951-foslevodopafoscarbidopa-showed-improvement-in-controlling-motor-fluctuations-compared-to-oral-levodopacarbidopa-medication-in-pivotal-phase-3-trial-in-patients-with-advanced-parkinsons-disease-301410482.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-28T08:15:00-04:00",
    "date_et": "2021-10-28"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-28 09:10:00",
    "publisher": "Seeking Alpha",
    "title": "Bargain Alert! 2 High Yield Funds To Buy Now",
    "image": "https://images.financialmodelingprep.com/news/bargain-alert-2-high-yield-funds-to-buy-now-20211028.jpg",
    "site": "seekingalpha.com",
    "text": "Bargain Alert! 2 High Yield Funds To Buy Now",
    "url": "https://seekingalpha.com/article/4462320-bargain-alert-2-high-yield-funds-to-buy-now",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-28T09:10:00-04:00",
    "date_et": "2021-10-28"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-28 10:30:00",
    "publisher": "The Motley Fool",
    "title": "Should Investors Worry About AbbVie?",
    "image": "https://images.financialmodelingprep.com/news/should-investors-worry-about-abbvie-20211028.jpg",
    "site": "fool.com",
    "text": "AbbVie is about to lose its patent on the world's top-selling drug, but it may not be as bad as it sounds.",
    "url": "https://www.fool.com/investing/2021/10/28/should-investors-worry-about-abbvie/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-28T10:30:00-04:00",
    "date_et": "2021-10-28"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-28 12:46:28",
    "publisher": "The Motley Fool",
    "title": "What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report",
    "image": "https://images.financialmodelingprep.com/news/what-investors-should-pay-attention-to-in-abbvies-q3-20211028.jpg",
    "site": "fool.com",
    "text": "In a word: Humira.",
    "url": "https://www.fool.com/investing/2021/10/28/what-investors-should-pay-attention-to-in-abbvies/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-28T12:46:28-04:00",
    "date_et": "2021-10-28"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 07:40:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie Reports Third-Quarter 2021 Financial Results",
    "image": "https://images.financialmodelingprep.com/news/abbvie-reports-thirdquarter-2021-financial-results-20211029.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Oct. 29, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2021.",
    "url": "https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2021-financial-results-301411843.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T07:40:00-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 07:45:00",
    "publisher": "Seeking Alpha",
    "title": "Dividend Aristocrats: 5 Buys And 5 Avoids For October",
    "image": "https://images.financialmodelingprep.com/news/dividend-aristocrats-5-buys-and-5-avoids-for-october-20211029.jpg",
    "site": "seekingalpha.com",
    "text": "Due to their reliability and above-average quality, Dividend Aristocrats can be great investments. One shouldn't buy at any price, however, and some of the Dividend Aristocrats look very pricy.",
    "url": "https://seekingalpha.com/article/4462936-dividend-aristocrats-5-buys-5-avoids-october",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T07:45:00-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 07:46:00",
    "publisher": "Reuters",
    "title": "AbbVie gets a shot in the arm from newer drug sales, lifts profit view",
    "image": "https://images.financialmodelingprep.com/news/abbvie-gets-a-shot-in-the-arm-from-newer-20211029.jpg",
    "site": "reuters.com",
    "text": "U.S. drugmaker AbbVie Inc on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.",
    "url": "https://www.reuters.com/article/abbvie-results/abbvie-gets-a-shot-in-the-arm-from-newer-drug-sales-lifts-profit-view-idUSKBN2HJ1I7",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T07:46:00-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 07:50:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder",
    "image": "https://images.financialmodelingprep.com/news/abbvies-cariprazine-vraylar-met-primary-endpoint-in-phase-3-20211029.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Oct. 29, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (VRAYLAR®) as an adjunctive treatment for patients with major depressive disorder (MDD).",
    "url": "https://www.prnewswire.com/news-releases/abbvies-cariprazine-vraylar-met-primary-endpoint-in-phase-3-study-as-an-adjunctive-treatment-for-major-depressive-disorder-301411566.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T07:50:00-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 08:04:53",
    "publisher": "Benzinga",
    "title": "AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend",
    "image": "https://images.financialmodelingprep.com/news/abbvie-stock-gains-after-hiking-fy21-earnings-outlook-annual-20211029.jpg",
    "site": "benzinga.com",
    "text": "AbbVie Inc (NYSE: ABBV) reports Q3 adjusted EPS of $3.33, higher than $2.83 reported a year ago and beating the consensus of $3.22. Overall sales increased 11.2% Y/Y to $14.34 billion, almost in line with the consensus of $14.32 billion.",
    "url": "https://www.benzinga.com/general/biotech/21/10/23741410/abbvie-stock-gains-after-hiking-fy21-earnings-outlook-annual-dividend",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T08:04:53-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 09:18:06",
    "publisher": "Benzinga",
    "title": "AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials",
    "image": "https://images.financialmodelingprep.com/news/abbvies-major-depressive-disorder-candidate-shows-mixed-result-in-latestage-20211029.jpg",
    "site": "benzinga.com",
    "text": "AbbVie Inc (NYSE: ABBV) has announced topline results from two Phase 3 trials, Study 3111-301-001 and Study 3111-302-001, of cariprazine (Vraylar) as an adjunctive treatment for major depressive disorder (MDD).  In Study 3111-301-001, cariprazine showed a statistically significant change from baseline to week six on the depression severity scale, with cariprazine at 1.5 mg/day achieving an improved score compared to placebo.",
    "url": "https://www.benzinga.com/general/biotech/21/10/23742113/abbvies-major-depressive-disorder-candidate-shows-mixed-result-in-late-stage-trials",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T09:18:06-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 10:42:25",
    "publisher": "Zacks Investment Research",
    "title": "AbbVie (ABBV) Tops Q3 Earnings Estimates",
    "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-tops-q3-earnings-estimates-20211029.jpg",
    "site": "zacks.com",
    "text": "AbbVie (ABBV) delivered earnings and revenue surprises of 3.10% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://www.zacks.com/stock/news/1819771/abbvie-abbv-tops-q3-earnings-estimates",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T10:42:25-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 12:44:55",
    "publisher": "Benzinga",
    "title": "Why AbbVie Shares Are Rising Today",
    "image": "https://images.financialmodelingprep.com/news/why-abbvie-shares-are-rising-today-20211029.jpg",
    "site": "benzinga.com",
    "text": "AbbVie Inc (NYSE: ABBV) is trading higher Friday after the company announced better-than-expected third-quarter financial results and raised guidance above estimates. AbbVie reported quarterly adjusted earnings of $3.33 per share, which beat the estimate of $3.22 per share.",
    "url": "https://www.benzinga.com/news/earnings/21/10/23752001/why-abbvie-shares-are-rising-today",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T12:44:55-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 14:38:16",
    "publisher": "Seeking Alpha",
    "title": "AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q3 2021 Results - Earnings Call Transcript",
    "image": "https://images.financialmodelingprep.com/news/abbvie-inc-abbv-ceo-rick-gonzalez-on-q3-2021-20211029.jpg",
    "site": "seekingalpha.com",
    "text": "AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q3 2021 Results - Earnings Call Transcript",
    "url": "https://seekingalpha.com/article/4463602-abbvie-inc-abbv-ceo-rick-gonzalez-on-q3-2021-results-earnings-call-transcript",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T14:38:16-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-29 17:31:00",
    "publisher": "PRNewsWire",
    "title": "U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)",
    "image": "https://images.financialmodelingprep.com/news/us-food-and-drug-administration-approves-vuity-pilocarpine-hci-20211029.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Oct. 29, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced the U.S. Food and Drug Administration (FDA) approval of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults.",
    "url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-vuity-pilocarpine-hci-ophthalmic-solution-1-25-the-first-and-only-eye-drop-to-treat-presbyopia-age-related-blurry-near-vision-301412259.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-29T17:31:00-04:00",
    "date_et": "2021-10-29"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-10-30 14:58:56",
    "publisher": "Invezz",
    "title": "Should I invest in AbbVie shares as it guides FY2021 EPS above Street forecast?",
    "image": "https://images.financialmodelingprep.com/news/should-i-invest-in-abbvie-shares-as-it-guides-20211030.jpg",
    "site": "invezz.com",
    "text": "On Friday, AbbVie Inc. (NYSE:ABBV) shares advanced 4.56% after announcing its fiscal third-quarter results. The company reported its most recent quarterly results before markets opened, beating analyst estimates on revenue and earnings.",
    "url": "https://invezz.com/news/2021/10/30/should-i-invest-in-abbvie-shares-as-it-guides-fy2021-eps-above-street-forecast/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-10-30T14:58:56-04:00",
    "date_et": "2021-10-30"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-01 07:35:49",
    "publisher": "24/7 Wall Street",
    "title": "5 Big Dividend Biotech and Pharmaceutical Stocks Have Strong Upside Potential",
    "image": "https://images.financialmodelingprep.com/news/5-big-dividend-biotech-and-pharmaceutical-stocks-have-strong-20211101.jpg",
    "site": "247wallst.com",
    "text": "For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.",
    "url": "https://247wallst.com/healthcare-business/2021/11/01/5-big-dividend-biotech-and-pharmaceutical-stocks-have-strong-upside-potential/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-01T07:35:49-04:00",
    "date_et": "2021-11-01"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-01 08:31:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021",
    "image": "https://images.financialmodelingprep.com/news/abbvie-highlights-innovative-research-from-its-rheumatology-portfolio-at-20211101.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Nov. 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ® (upadacitinib), SKYRIZI® (risankizumab) and HUMIRA® (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2021), to be held virtually Nov. 3-9.",
    "url": "https://www.prnewswire.com/news-releases/abbvie-highlights-innovative-research-from-its-rheumatology-portfolio-at-acr-convergence-2021-301412850.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-01T08:31:00-04:00",
    "date_et": "2021-11-01"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-01 08:46:24",
    "publisher": "Seeking Alpha",
    "title": "AbbVie Boosts Dividend In October; Emerson, 14 Others To Announce Increases In First Half Of November",
    "image": "https://images.financialmodelingprep.com/news/abbvie-boosts-dividend-in-october-emerson-14-others-to-20211101.jpeg",
    "site": "seekingalpha.com",
    "text": "Despite the economic uncertainty with supply chain issues and the potential for tax hikes, dividend increases in October were as expected. Double-digit boosts came from Amphenol, Brown & Brown, Lincoln Electric, Stepan Company, and Waste Connections. Biopharmaceutical company AbbVie also announced its newest increase in late October.",
    "url": "https://seekingalpha.com/article/4464038-16-companies-to-announce-increases",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-01T08:46:24-04:00",
    "date_et": "2021-11-01"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-02 18:44:37",
    "publisher": "Seeking Alpha",
    "title": "Endo: A Win In California But Equity Value Still A Question",
    "image": "https://images.financialmodelingprep.com/news/endo-a-win-in-california-but-equity-value-still-20211102.jpg",
    "site": "seekingalpha.com",
    "text": "Endo: A Win In California But Equity Value Still A Question",
    "url": "https://seekingalpha.com/article/4464661-endo-win-in-california-but-equity-value-still-question",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-02T18:44:37-04:00",
    "date_et": "2021-11-02"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-03 13:00:36",
    "publisher": "Stockmarket.com",
    "title": "Best Stocks To Buy Today? 4 Dividend Stocks To Check Out",
    "image": "https://images.financialmodelingprep.com/news/best-stocks-to-buy-today-4-dividend-stocks-to-check-20211103.jpg",
    "site": "stockmarket.com",
    "text": "Dividend stocks could be worth paying attention to as the Federal Reserve may look to pull back its monetary support.",
    "url": "https://stockmarket.com/featured/best-stocks-to-buy-today-4-dividend-stocks-to-check-out-2021-11-03",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-03T13:00:36-04:00",
    "date_et": "2021-11-03"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-03 14:50:00",
    "publisher": "Seeking Alpha",
    "title": "Dividend Income Summary: Lanny's October 2021 Summary",
    "image": "https://images.financialmodelingprep.com/news/dividend-income-summary-lannys-october-2021-summary-20211103.jpg",
    "site": "seekingalpha.com",
    "text": "In October, we (my wife and I) received a total of $966.97 of dividend income.",
    "url": "https://seekingalpha.com/article/4464985-dividend-income-summary-lannys-october-2021-summary",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-03T14:50:00-04:00",
    "date_et": "2021-11-03"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-04 09:05:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting",
    "image": "https://images.financialmodelingprep.com/news/abbvie-to-highlight-new-advances-in-blood-cancer-research-20211104.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Nov. 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology (ASH) Annual Meeting (December 11-14) in Atlanta, Georgia.",
    "url": "https://www.prnewswire.com/news-releases/abbvie-to-highlight-new-advances-in-blood-cancer-research-and-expanding-oncology-pipeline-at-63rd-ash-annual-meeting-301416402.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-04T09:05:00-04:00",
    "date_et": "2021-11-04"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-04 09:07:00",
    "publisher": "GlobeNewsWire",
    "title": "Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)",
    "image": "https://images.financialmodelingprep.com/news/genmab-announces-multiple-abstracts-to-be-presented-at-the-20211104.jpg",
    "site": "globenewswire.com",
    "text": "Media Release",
    "url": "https://www.globenewswire.com/news-release/2021/11/04/2327660/0/en/Genmab-Announces-Multiple-Abstracts-to-be-Presented-at-the-63rd-Annual-Meeting-and-Exposition-of-the-American-Society-of-Hematology-ASH.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-04T09:07:00-04:00",
    "date_et": "2021-11-04"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-05 08:00:00",
    "publisher": "Seeking Alpha",
    "title": "AbbVie: Don't Worry Be Happy",
    "image": "https://images.financialmodelingprep.com/news/abbvie-dont-worry-be-happy-20211105.jpg",
    "site": "seekingalpha.com",
    "text": "AbbVie: Don't Worry Be Happy",
    "url": "https://seekingalpha.com/article/4465863-abbvie-abbv-undervalued-dividend-growth-stock",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-05T08:00:00-04:00",
    "date_et": "2021-11-05"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-05 10:06:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021",
    "image": "https://images.financialmodelingprep.com/news/abbvie-presents-integrated-efficacy-and-safety-data-from-two-20211105.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Nov. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the efficacy and safety of risankizumab (SKYRIZI®) in adult patients with active psoriatic arthritis (PsA).",
    "url": "https://www.prnewswire.com/news-releases/abbvie-presents-integrated-efficacy-and-safety-data-from-two-phase-3-trials-on-risankizumab-skyrizi-in-psoriatic-arthritis-at-acr-convergence-2021-301417639.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-05T10:06:00-04:00",
    "date_et": "2021-11-05"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-05 16:37:25",
    "publisher": "Seeking Alpha",
    "title": "112 S&P High Yield Dividend Aristocrats Deliver More Dog Per Dollar",
    "image": "https://images.financialmodelingprep.com/news/112-sp-high-yield-dividend-aristocrats-deliver-more-dog-20211105.jpg",
    "site": "seekingalpha.com",
    "text": "\"S&P High Yield Dividend Aristocrats index is designed to measure the performance of companies within the S&P Composite 1500 that have consistently increased dividends every year for at least 20 years.\" - spindices.com.",
    "url": "https://seekingalpha.com/article/4466177-112-s-and-p-high-yield-dividend-aristocrats-deliver-more-dog-per-dollar",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-05T16:37:25-04:00",
    "date_et": "2021-11-05"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-06 09:00:00",
    "publisher": "Seeking Alpha",
    "title": "The Near-Perfect Portfolio For The Good Times And Bad",
    "image": "https://images.financialmodelingprep.com/news/the-nearperfect-portfolio-for-the-good-times-and-bad-20211106.jpeg",
    "site": "seekingalpha.com",
    "text": "No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited drawdowns in case of deep corrections.",
    "url": "https://seekingalpha.com/article/4465404-near-perfect-portfolio-good-times-and-bad",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-06T09:00:00-04:00",
    "date_et": "2021-11-06"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-07 05:52:00",
    "publisher": "The Motley Fool",
    "title": "Investing $100,000 in These Dividend Stocks Could Give You Nearly $6,000 in Steady Annual Income",
    "image": "https://images.financialmodelingprep.com/news/investing-100000-in-these-dividend-stocks-could-give-you-20211107.jpg",
    "site": "fool.com",
    "text": "You should be able to count on these dividends over the long term.",
    "url": "https://www.fool.com/investing/2021/11/07/investing-100000-in-these-dividend-stocks-could-gi/",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-07T05:52:00-05:00",
    "date_et": "2021-11-07"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-08 08:30:00",
    "publisher": "PRNewsWire",
    "title": "Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting",
    "image": "https://images.financialmodelingprep.com/news/allergan-an-abbvie-company-to-present-new-data-from-its-20211108.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Nov. 8, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopia; additional analyses on DURYSTA® (bimatoprost intracameral implant); and three real-world data studies on the glaucoma patient journey at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting, November 12-15.",
    "url": "https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the-aao-american-academy-of-ophthalmology-2021-annual-meeting-301418026.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-08T08:30:00-05:00",
    "date_et": "2021-11-08"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-09 08:31:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis",
    "image": "https://images.financialmodelingprep.com/news/abbvie-to-present-new-longterm-analysis-evaluating-the-sustainability-20211109.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ® (upadacitinib; 15 mg, once daily) in patients with moderate to severe rheumatoid arthritis (RA) on stable background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with prior inadequate response or intolerance to at least one biologic DMARD.",
    "url": "https://www.prnewswire.com/news-releases/abbvie-to-present-new-long-term-analysis-evaluating-the-sustainability-of-response-to-rinvoq-upadacitinib-among-patients-with-rheumatoid-arthritis-301419810.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-09T08:31:00-05:00",
    "date_et": "2021-11-09"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-09 08:45:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021",
    "image": "https://images.financialmodelingprep.com/news/abbvie-presents-new-efficacy-data-on-upadacitinib-rinvoq-in-20211109.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from new post-hoc analyses from the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials assessing the efficacy of upadacitinib (RINVOQ®) on axial symptoms in adult patients with active psoriatic arthritis (PsA) and axial involvement.",
    "url": "https://www.prnewswire.com/news-releases/abbvie-presents-new-efficacy-data-on-upadacitinib-rinvoq-in-people-with-active-psoriatic-arthritis-and-axial-involvement-at-acr-convergence-2021-301419805.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-09T08:45:00-05:00",
    "date_et": "2021-11-09"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-09 15:22:00",
    "publisher": "Seeking Alpha",
    "title": "Dividend Income Summary: Bert's October 2021 Report",
    "image": "https://images.financialmodelingprep.com/news/dividend-income-summary-berts-october-2021-report-20211109.jpg",
    "site": "seekingalpha.com",
    "text": "Dividend Income Summary: Bert's October 2021 Report",
    "url": "https://seekingalpha.com/article/4467503-dividend-income-summary-berts-october-2021-report",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-09T15:22:00-05:00",
    "date_et": "2021-11-09"
  },
  {
    "symbol": "ABBV",
    "publishedDate": "2021-11-10 08:30:00",
    "publisher": "PRNewsWire",
    "title": "AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025",
    "image": "https://images.financialmodelingprep.com/news/abbvie-university-of-chicago-extend-research-collaboration-to-support-20211110.jpg",
    "site": "prnewswire.com",
    "text": "NORTH CHICAGO, Ill. and CHICAGO, Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology research.",
    "url": "https://www.prnewswire.com/news-releases/abbvie-university-of-chicago-extend-research-collaboration-to-support-preclinical-oncology-research-through-2025-301420540.html",
    "ticker": "ABBV",
    "event_date": "2021-10-29",
    "window_start": "2021-10-22",
    "window_end": "2021-11-12",
    "publishedDateET": "2021-11-10T08:30:00-05:00",
    "date_et": "2021-11-10"
  }
]